
Get answers to your Myelodysplastic Syndromes questions.
Plasma cell dyscrasia; Plasma cell myeloma; Malignant plasmacytoma; Plasmacytoma of bone; Myeloma - multiple
The goal of treatment is to relieve symptoms.
People who have mild disease or a questionable diagnosis are usually carefully monitored without treatment. Some people have a slow-developing form of multiple myeloma that takes years to cause symptoms.
Treatment begins when the disease becomes worse or causes symptoms.
Chemotherapy and radiation therapy may be performed to relieve bone pain or treat a bone tumor.
Bone marrow transplantation in younger patients has been shown to increase disease-free and overall survival, but it has significant risks.
Medications for multiple myeloma include decadron, melophalan, thalidomide, lenalidomide (Revlimid), and bortezomib (Velcade). Bisphosphonates are used to prevent fractures.
People with multiple myeloma should drink plenty of fluids to prevent dehydration and help maintain proper kidney function. They should also be cautious when having x-ray tests that use contrast dye.
Chemotherapy and transplants rarely lead to a permanent cure.
The stress of illness may be eased by joining a support group whose members share common experiences and problems. See: Cancer - support group
Survival of people with multiple myeloma depends on the patient's age and the stage of disease. Some cases are very aggressive, while others take years to get worse.
Kidney failure is a frequent complication. Other complications may include:
Call your health care provider if you experience decreased urine output.
Call your provider if you have multiple myeloma and infection develops, or numbness, loss of movement, or loss of sensation develops.
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Multiple Myeloma. National Comprehensive Cancer Network; 2009. Version 2.2009.
Rajkumar S, Kyle R. Plasma cell disorders. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007: chap 198.